Crossmark

731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0731

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Hollebecque, Antoine

Lopez, Juanita

Piha-Paul, Sarina

Dowlati, Afshin

Patnaik, Amita

Galvao, Vladimir

Buckorny, Bruno

Sehgal, Kartik

Kingsley, Edwin

Sanborn, Rachel

Peters, Solange

Sun, Yan

Patilea-Vrana, Gabriela

Nazarenko, Natalya

Calvo, Emiliano
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04389632 at ClinicalTrials.gov

Documents that mention this clinical trial

1186 SGN-B6A induces immunogenic cell death as a secondary mechanism of action
https://doi.org/10.1136/jitc-2022-sitc2022.1186

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
https://doi.org/10.1200/jco.2023.41.16_suppl.3024

731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)
https://doi.org/10.1136/jitc-2022-sitc2022.0731

Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).
https://doi.org/10.1200/jco.2024.42.16_suppl.8521

Document is current

Any future updates will be listed below